Alemtuzumab
- PDF / 169,433 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 23 Downloads / 154 Views
1 S
Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy following off label use: 3 case reports In a retrospective study involving 2,788 kidney transplant recipients, who received alemtuzumab or antithymocyte-globulin [rabbit anti-thymocyte globulin] between 2002 and 2018, 3 patients [ages and sexes not stated] were described, who developed Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy during treatment with alemtuzumab. The use of alemtuzumab in kidney transplant recipient was considered as off label. Three patients started receiving off label treatment with alemtuzumab [dosages and routes not stated] following kidney transplantation. The patients presented with sensory impairment and limb weakness at 4 months (1 patient), 8 months (1 patient) and 42 months (1 patient), respectively after use of alemtuzumab. The patients were diagnosed with alemtuzumab-related inflammatory neuropathy: chronic inflammatory demyelinating polyradiculoneuropathy (1 patient) and Guillain-Barre syndrome (2 patients) [duration of treatments to reactions onset not stated]. One of the patients with Guillain-Barre syndrome died due to malignancy. The remaining two patients recovered following unspecified therapy. Van Der Zwan M, et al. Inflammatory neuropathy after alemtuzumab therapy in kidney transplant recipients. Transplantation 104 (Suppl. 3): S382, Sep 2020. Available from: 803519064 URL: http://doi.org/10.1097/01.tp.0000700504.04501.54 [abstract]
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
